Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

86.57 +4.97 (+6.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗

January 04, 2026

Not all of these predictions may come true. But at least a few of them will likely do so.

Via The Motley Fool

Topics Artificial Intelligence Economy

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗

January 01, 2026

Via Chartmill

Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗

December 30, 2025

These predictions were easy.

Via The Motley Fool

Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗

December 08, 2025

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Via The Motley Fool

Topics Regulatory Compliance

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

December 19, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

December 08, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 ↗

December 03, 2025

Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.

Via The Motley Fool

Topics Earnings

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

December 01, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗

November 29, 2025

Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.

Via Chartmill

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗

November 27, 2025

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

Via The Motley Fool

Topics Regulatory Compliance

Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗

November 27, 2025

One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.

Via The Motley Fool

Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗

November 27, 2025

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.

Via The Motley Fool

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 25, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

November 07, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗

November 05, 2025

Via Benzinga

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 04, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 03, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

October 28, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗

October 18, 2025

Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.

Via Chartmill

8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗

September 27, 2025

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.

Via Chartmill

This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 24, 2025

Via Benzinga

Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews ↗

September 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.